Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 17, 2002
Event: Announcement of a definitive merger agreement with Genomic Solutions Inc. (GNSL).
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain periodic financial statements (e.g., revenue, profit, cash flow, or debt levels) for the reporting period.
| Metric | Value |
|---|---|
| Merger Consideration (Cash) | $9,000,000 |
| Merger Consideration (Stock) | 3,200,000 shares of Harvard Bioscience common stock |
| Revenue/Profit/Cash Flow | Not provided in this filing |
Material Changes
The primary material change is the execution of an Agreement and Plan of Merger. Under the terms, GNSL will merge into HAG Acq. Corp., a wholly-owned subsidiary of Harvard Bioscience. All outstanding GNSL common stock will be converted into the cash and stock consideration noted above.
Guidance, Outlook, and Risks
- Conditions to Closing: The merger is subject to customary closing conditions, regulatory approvals, and the approval of GNSL stockholders.
- Voting Agreements: Harvard Bioscience has secured voting agreements with GNSL stockholders controlling approximately 38% of outstanding GNSL shares to vote in favor of the merger.
- Forward-Looking Statements: The filing includes a disclaimer that forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from anticipated results. Investors are directed to the "Important Factors That May Affect Future Operating Results" section of the Company's 2001 Form 10-K for details.
- Financial Information: No pro forma financial information or financial statements of the acquired business are included in this filing.
Investor Verification Checklist
- Verify the status of GNSL stockholder approval for the merger.
- Confirm receipt of necessary regulatory approvals.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific closing conditions and representations.
- Assess the impact of the 3.2 million new shares on existing shareholder dilution.
- Examine the 2001 Form 10-K for historical risk factors relevant to this transaction.